Thus, our data provide support for targeting AMPK by the use of pharmacological, as well as nutraceutical compounds, to strengthen intestinal epithelial barrier functions and to exert health beneficial effects on leaky gut, predisposing individuals to intestinal bowel disease, obesity and diabetes. The gene discussed is PRKAA1; the disease is obesity disorder.